INDICATIONS AND USAGE（适应症）

VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

DOSAGE（服用剂量）

The recommended dosage is either VYNDAQEL 80 mg (four 20-mg tafamidis meglumine capsules) orally once daily or VYNDAMAX 61 mg (one 61-mg tafamidis capsule) orally once daily.

VYNDAMAX and VYNDAQEL are not substitutable on a per mg basis.

ADVERSE REACTIONS（不良反应）

There were no known side effects that happened during treatment with VYNDAQEL or VYNDAMAX in people with cardiomyopathy of transthyretin-mediated amyloidosis.

For full information, please refer to:

https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/1b4121ee-a733-4456-a917-be2603477839/spl-doc?hl=Vyndaqel

Vyndaqelinformation